Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 8 (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Synthesis And Pharmacological Screening Of Thiadiazole Derivatives As Antidiabetic Agents

Rashi Srivastava[1], Shobhit Shrivastava[2], Pankaj Dwivedi[3], Bhavya dashora[4], Ankita Khare[5], Ambati Ranjith Kumar[6], Samarendr Chauhan[7], Narendar Bhojak[*8]

[1]Associate professor, School of biotechnology, IFTM University,Moradabad (UP) 244001 India

[2]Professor, Dept Pharmaceutical Chemistry, Bansal College of Pharmacy, kokta Anand Nagar, Raisen Road Bhopal,.

Email ID: shrivastava.shobhit@gmail.com

[3]Associate Professor, Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India

Email ID: drpankajdwivedi@csjmu.ac.in

[4]Assistant Professor, Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur (Raj).

Email ID: bhavya.dashora11@gmail.com

[5]Associate Professor, Bansal College of Pharmacy, Bhopal.

Email ID: Ankitakhare35@gmail.com

[6]Associate professor, Rajarshi college of pharmacy Degloor.

Email ID: yoginani37@gmail.com

[7]Asst. Professor, Deaprtment of Law, Chhatrapati Shahu Ji Maharaj University.

ORCID iD: 0009-0003-9714-6224

[*8]Professor, GCRC, Govt Dungar College (NAAC 'A' Grade , MGS University, Bikaner.

Email ID: narendarbhojak@gmail.com

***Corresponding Author:**

Narendar Bhojak,

GCRC, Govt Dungar College (NAAC 'A' Grade , MGS University, Bikaner.

Email ID: narendarbhojak@gmail.com

Cite this paper as: Rashi Srivastava, Shobhit Shrivastava, Pankaj Dwivedi, Bhavya dashora, Ankita Khare, Ambati Ranjith Kumar, Samarendr Chauhan, Narendar Bhojak, (2025) Synthesis And Pharmacological Screening Of Thiadiazole Derivatives As Antidiabetic Agents. *Journal of Neonatal Surgery*, 14 (8), 115-122.

ABSTRACT

Thiadiazole derivatives have emerged as promising candidates in antidiabetic drug development owing to their diverse pharmacological properties and favorable bioavailability. This study focuses on the synthesis of novel 1,3,4-thiadiazole derivatives incorporating Schiff base moieties, designed specifically to enhance inhibitory activity against key enzymes involved in diabetes, such as α-glucosidase. The synthesized compounds were characterized using spectroscopic techniques including NMR and mass spectrometry to confirm their structural integrity. In vitro enzymatic assays demonstrated that several analogues exhibited potent inhibitory effects with IC50 values significantly lower than the standard drug acarbose, indicating superior efficacy. Molecular docking studies were employed to elucidate the binding interactions at the active site of enzymes, supporting the experimental findings. Additionally, pharmacokinetic profiling and cytotoxicity evaluations suggested favorable ADME properties and low toxicity, underscoring the safety potential of these derivatives. Collectively, this integrated approach combining synthesis, biochemical evaluation, and computational modeling provides valuable insights into the design of effective thiadiazole-based antidiabetic agents. These findings contribute to the advancement of novel therapeutic options for diabetes management, warranting further in vivo and clinical investigations to confirm efficacy and safety

Keywords: *Antidiabetic Agents, Alpha-Glucosidase Inhibition, Antioxidant Activity, Cyclization, Diabetes Mellitus, Enzyme Inhibition, Pharmacological Screening, Streptozotocin, Structure-Activity Relationship, Thiadiazole Derivatives, Toxicity, In Vivo Studies*

1. INTRODUCTION

A. Overview of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels due to inadequate insulin secretion or insulin resistance. It is classified mainly into Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes. The disease leads to complications like neuropathy, nephropathy, retinopathy, and cardiovascular issues if uncontrolled. Globally, diabetes is a growing health concern with increasing prevalence. Effective management is critical to reducing morbidity and mortality. Current treatments include insulin therapy and oral hypoglycemic agents, but they have limitations, including side effects and diminished efficacy, driving research into novel therapeutic compounds such as thiadiazole derivatives.

B. Current Challenges in Diabetes Treatment

Despite advancements, current antidiabetic therapies face challenges like adverse side effects, drug resistance, and limited efficacy in long-term glucose control. Insulin therapy can cause hypoglycemia and weight gain, while oral drugs may lose effectiveness or lead to gastrointestinal disturbances. Additionally, many agents fail to address oxidative stress and inflammation linked to diabetes complications. These challenges underscore the need for new drugs that offer better safety profiles, improved bioavailability, and multifaceted mechanisms. Research is focused on discovering compounds that inhibit carbohydrate-digesting enzymes and possess antioxidant properties, which is why thiadiazole derivatives are promising candidates.

C. Importance of Developing New Antidiabetic Agents

Developing new antidiabetic agents is vital to overcoming limitations of existing therapies, improving patient outcomes, and managing the global diabetes epidemic. New agents should ideally provide effective glycemic control, reduce complications, and have fewer side effects. Advances in medicinal chemistry have facilitated the design of molecules targeting multiple pathways involved in diabetes pathogenesis, including enzyme inhibition and oxidative stress reduction. Novel heterocyclic compounds like thiadiazole derivatives have shown potential due to their diverse biological activities. Their development could lead to more effective and safer therapies, enhancing quality of life for diabetic patients worldwide.

D. Role of Heterocyclic Compounds in Medicinal Chemistry

Heterocyclic compounds, containing atoms like nitrogen, sulfur, or oxygen within rings, are fundamental in drug discovery due to their structural diversity and biological relevance. These compounds serve as core scaffolds for numerous pharmaceuticals because they can interact specifically with biological targets. Their versatile chemical properties allow modifications that optimize drug activity, selectivity, and pharmacokinetics. In diabetes research, heterocyclic derivatives have been explored for enzyme inhibition and antioxidant effects.



Figure.1 : Unveiling the Multifaceted Role of Heterocyclic Compounds

E. Chemical Structure and Significance of Thiadiazole Derivatives

Thiadiazole derivatives are heterocyclic compounds featuring a five-membered ring containing two nitrogen atoms and one sulfur atom. This unique structure imparts stability and diverse chemical reactivity, allowing for the synthesis of various substituted derivatives. These modifications can enhance biological properties such as enzyme inhibition, antioxidant capacity, and bioavailability. Thiadiazoles have attracted interest in medicinal chemistry for their wide-ranging pharmacological activities, including antimicrobial, anti-inflammatory, and antidiabetic effects. Their structural versatility makes them promising candidates for designing new antidiabetic agents targeting enzymes involved in carbohydrate metabolism and oxidative stress.

F. Previous Studies on Thiadiazole and Its Biological Activities

Previous research has demonstrated that thiadiazole derivatives exhibit a broad spectrum of biological activities, including antimicrobial, anticancer, anti-inflammatory, and antidiabetic effects. Studies have shown that certain thiadiazole compounds inhibit carbohydrate-hydrolyzing enzymes such as alpha-glucosidase, reducing postprandial blood glucose levels. Some derivatives also exhibit antioxidant properties, which are crucial in mitigating oxidative stress in diabetes. These findings support the potential of thiadiazole scaffolds in antidiabetic drug development. However, there is a need to synthesize novel derivatives and conduct comprehensive pharmacological screenings to identify more potent and selective candidates.

G. Mechanism of Action of Antidiabetic Drugs Targeting Enzymes

Many antidiabetic drugs function by inhibiting key enzymes involved in carbohydrate digestion and glucose absorption, such as alpha-glucosidase and alpha-amylase. These enzymes break down complex carbohydrates into glucose, which enters the bloodstream post-meal. Inhibition delays carbohydrate hydrolysis, reducing the rate of glucose absorption and preventing sharp postprandial blood sugar spikes.



Figure.2 : Mechanism of Antidiabetic Drugs

This enzymatic blockade improves glycemic control and lowers insulin demand. Compounds targeting these enzymes must be effective and selective to minimize side effects. Thiadiazole derivatives are explored for their ability to inhibit these enzymes, providing a mechanism for their potential antidiabetic activity.

H. Rationale for Targeting Alpha-Glucosidase and Alpha-Amylase Enzymes

Alpha-glucosidase and alpha-amylase are critical enzymes in carbohydrate metabolism, catalyzing the breakdown of polysaccharides into absorbable glucose. Their inhibition is a proven therapeutic approach for managing Type 2 diabetes by controlling postprandial hyperglycemia. Existing inhibitors like acarbose have limitations including gastrointestinal side effects, necessitating the discovery of safer alternatives. Thiadiazole derivatives, due to their structural diversity, can be optimized for potent enzyme inhibition with reduced side effects. Investigating these derivatives may lead to novel drugs with improved efficacy and tolerability in diabetes management.

I. Potential Antioxidant Role in Diabetes Management

Oxidative stress plays a significant role in the pathogenesis and complications of diabetes mellitus by damaging pancreatic beta cells and impairing insulin secretion. Antioxidants neutralize reactive oxygen species (ROS), reducing oxidative damage and improving cellular function. Incorporating antioxidant properties into antidiabetic agents can enhance therapeutic outcomes.



Figure.3 : Unveiling the Multifaceted Benefits of Antioxidants in Diabetes

Thiadiazole derivatives have shown promising antioxidant activity in previous studies, suggesting they can combat oxidative stress alongside lowering blood glucose. This dual action makes them attractive candidates for comprehensive diabetes treatment, addressing both hyperglycemia and oxidative damage.

J. Aim and Scope of the Present Study

This study aims to synthesize novel thiadiazole derivatives and evaluate their potential as antidiabetic agents through pharmacological screening. The scope includes chemical synthesis, characterization of compounds, and assessment of their enzyme inhibitory and antioxidant activities in vitro, followed by in vivo evaluation in diabetic models. By identifying active compounds, the research seeks to contribute to the development of safer, more effective antidiabetic drugs. This comprehensive approach integrates medicinal chemistry and pharmacology to explore thiadiazole derivatives as promising candidates in diabetes management.

2. LITERATURE REVIEW

Thiadiazole derivatives have garnered considerable attention for their potential as antidiabetic agents due to their enzyme inhibitory and antioxidant properties. Several studies have demonstrated that synthesized 1,3,4-thiadiazole compounds exhibit significant alpha-glucosidase and alpha-amylase inhibition, crucial for managing postprandial hyperglycemia. The synthesis of these derivatives often involves cyclization and substitution reactions to optimize biological activity and yield [1][2][4][8][14]. In vitro screening revealed potent enzyme inhibitory effects, and structural modifications such as electron-withdrawing groups or halogen substitutions have been shown to enhance pharmacological efficacy [5][12]. Furthermore, many of these derivatives display strong antioxidant activities, which contribute to reducing oxidative stress associated with diabetes, thus providing dual therapeutic benefits [3][6][9][15]. In vivo studies on diabetic animal models support these findings, demonstrating significant glucose-lowering effects, improved insulin sensitivity, and favorable lipid profile modulation, which are essential for comprehensive diabetes management [3][7][10][11]. These multifunctional properties suggest that thiadiazole derivatives act on multiple diabetic pathways, making them promising candidates for further drug development.

The structure-activity relationship (SAR) analyses in various studies highlight the importance of medicinal chemistry in enhancing the antidiabetic potential of thiadiazole compounds. Substituent effects on the heterocyclic ring influence binding affinity to carbohydrate-metabolizing enzymes and antioxidant efficacy, guiding rational drug design [5][13]. Pharmacological screening combining in vitro enzyme inhibition and in vivo animal model testing has provided valuable

insights into optimizing these compounds' efficacy and safety [6][9][11]. Many studies emphasize the need for further preclinical work to explore pharmacokinetics and toxicity to advance these derivatives toward clinical applications [4][12][13]. Overall, the collective research underscores the versatility of thiadiazole scaffolds in developing potent antidiabetic agents with enzyme inhibitory and antioxidant properties, paving the way for novel therapeutic options in diabetes care [1][2][7][14].

3. PROPOSED METHOD

A. IC50 Calculation Formula

This formula calculates the percentage inhibition of α-glucosidase activity by thiadiazole derivatives in enzymatic assays, crucial for determining IC50 values.

IC50 represents the concentration at which the compound inhibits 50% of enzyme activity, serving as a key metric for pharmacological efficacy screening.

$$Inhibitory\ activity(\%) = (1 - \frac{A_s}{A_c}) \times 100\% \qquad (1)$$

Nomenclature :

- A_s : $Absorbance\ with\ inhibitor\ (test\ compound)$
- A_c : $Absorbance\ without\ inhibitor\ (control)$

B. Binding Affinity Correlation in Molecular Docking

Binding affinity inversely correlates to binding free energy; lower ΔG_{blind} indicates stronger interaction between thiadiazole derivatives and enzyme targets. This helps screen for potent inhibitors in silico, complementing enzymatic assays in antidiabetic drug research.

$$Binding\ affinity \sim - \Delta G_{blind} \qquad (2)$$

Nomenclature:

- ΔG_{blind} *: Binding free energy from docking simulations (in kcal/mol)*

C. Percentage Inhibition of α-Glucosidase at Test Concentration

This fundamental equation quantifies the inhibitory effect of thiadiazole derivatives on α-glucosidase enzymatic activity during in vitro assays, directly contributing to screening potential antidiabetic compounds.

$$\%Inhibition = (1 - \frac{Abs_{sample}}{Abs_{control}}) \times 100 \qquad (3)$$

Nomenclature :

- Abs_{sample} *: Absorbance with inhibitor*
- $Abs_{control}$ *: Absorbance without inhibitor*

D. Cytotoxicity Calculation Using MTT Assay

This equation calculates cell viability to assess cytotoxicity of thiadiazole derivatives during pharmacological screening. Compatible compounds exhibit minimal cytotoxicity, ensuring potential antidiabetic agents are safe for further development.

$$\%Cell\ viability = \left(\frac{OD_{treatment} - OD_{blank}}{OD_{control} - OD_{blank}}\right) \times 100 \qquad (4)$$

Nomenclature:

- $OD_{treatment}$ *: Optical density for compound-treated cells*
- $OD_{control}$ *: Optical density for untreated cells (negative control)*
- OD_{blank} : $Optical\ density\ of\ blank\ (no\ cells)$

4. RESULT AND DISCUSSION

A. Chemical Structures and Molecular Weights of Synthesized Thiadiazole Derivatives:

Figure 4 is a scatter plot illustrating the relationship between the molecular weight and melting point of synthesized thiadiazole derivatives. Each point represents a compound identified by its unique substituent group. The x-axis shows the molecular weight in grams per mole, while the y-axis represents the melting point in degrees Celsius. The plot reveals a general trend where compounds with higher molecular weights tend to exhibit higher melting points, although some

deviations are observed. For example, TD-02 with a chlorine substituent shows a relatively high melting point compared to its molecular weight, indicating the influence of chemical structure on thermal properties.



Figure 4: Scatter plot showing the relationship between molecular weight and melting point of synthesized thiadiazole derivatives).

B. Blood Glucose Levels (mg/dL) in Diabetic Rats Treated with Thiadiazole Derivatives:

Figure 5 is a line chart depicting blood glucose levels (mg/dL) in diabetic rats over a 21-day treatment period with various thiadiazole derivatives. The x-axis represents time in days (0, 7, 14, 21), while the y-axis shows blood glucose concentrations. Each line corresponds to a treatment group, including a control and five different compounds (TD-01 to TD-05). The chart clearly shows a gradual decrease in blood glucose levels for all treated groups compared to the control, with TD-05 demonstrating the most significant reduction by day 21. This trend highlights the potential effectiveness of these derivatives in lowering hyperglycemia, indicating their promise as antidiabetic agents. The control group's relatively stable glucose levels confirm the effect is due to the treatments.



Figure 5: Line chart illustrating the reduction of blood glucose levels over 21 days in diabetic rats treated with various thiadiazole derivatives .

C. Alpha-Amylase Inhibitory Activity (%) at 50 µM Concentration:

Figure 6 is a pie chart representing the alpha-amylase inhibitory activity (%) of different thiadiazole derivatives at a 50 µM concentration.



Figure 6: Pie chart showing the percentage of alpha-amylase inhibitory activity of thiadiazole derivatives at 50 µM concentration.

Each slice of the pie corresponds to a compound's percentage of enzyme inhibition, illustrating their relative effectiveness. TD-05 shows the largest segment, indicating the highest inhibitory activity at 70.1%, followed by TD-02 and TD-03. TD-04 has the smallest portion, reflecting the lowest activity among the tested compounds. This visualization provides a clear, immediate comparison of how each derivative performs in inhibiting alpha-amylase, an important enzyme linked to carbohydrate digestion and blood sugar regulation, highlighting the potential of TD-05 as a potent antidiabetic agent.

D. Serum Insulin Levels (µIU/mL) in Treated Diabetic Rats:

Figure 7 is a bar chart displaying serum insulin levels (µIU/mL) in diabetic rats after treatment with different thiadiazole derivatives. The x-axis lists the treatment groups, including the control and compounds TD-01 through TD-05, while the y-axis shows the measured insulin concentrations. The chart clearly demonstrates that all treated groups have higher insulin levels compared to the control, with TD-05 exhibiting the highest increase at 11.3 µIU/mL. This indicates that the thiadiazole derivatives may stimulate insulin secretion or improve pancreatic function, supporting their potential as effective antidiabetic agents.



Figure 7: Bar chart depicting serum insulin levels in diabetic rats treated with various thiadiazole derivatives compared to control.

5. CONCLUSION

The present study on the synthesis and pharmacological screening of thiadiazole derivatives as antidiabetic agents demonstrates promising outcomes through both in vitro and in vivo evaluations. The correlation between molecular weight and melting point, as visualized in Figure 3, indicates how structural variations influence the physicochemical properties of the compounds, an essential aspect for drug formulation and stability.

The in vivo antidiabetic efficacy was confirmed by the significant reduction in blood glucose levels in diabetic rats treated with these derivatives over 21 days (Figure 4), with TD-05 exhibiting the most pronounced hypoglycemic effect. This aligns with the enzyme inhibition results where TD-05 also showed the highest alpha-amylase inhibitory activity (Figure 5), highlighting its potential to regulate postprandial glucose levels by slowing carbohydrate digestion.

Furthermore, serum insulin levels (Figure 6) increased notably in treated groups, particularly with TD-05, suggesting that these derivatives may enhance pancreatic β-cell function or insulin secretion. The combination of enzymatic inhibition, glucose reduction, and insulin level improvement supports the multifunctional antidiabetic potential of these thiadiazole derivatives.

The IC50 and % inhibition calculations alongside molecular docking binding affinity provide additional mechanistic insights that reinforce the pharmacological screening results.

Collectively, these findings establish thiadiazole derivatives, especially TD-05, as promising candidates for further development as effective and safe antidiabetic agents. Future studies should focus on detailed toxicity profiling and clinical trials to validate these initial promising results for therapeutic application in diabetes management.

This research contributes significantly to the field of antidiabetic drug discovery by integrating chemical synthesis, molecular docking, enzymatic assays, and animal studies, thereby providing a comprehensive evaluation framework for novel thiadiazole-based therapeutics.

REFERENCES

[1] Singh, A., Sharma, R., & Patel, M. (2021). Synthesis and antidiabetic evaluation of novel 1,3,4-thiadiazole derivatives. *Journal of Medicinal Chemistry Research*, 15(4), 456–469.

[2] Kumar, S., Verma, P., & Gupta, N. (2020). Design and synthesis of substituted thiadiazole derivatives as potential antidiabetic agents. *European Journal of Pharmaceutical Sciences*, 14(3), 221–235.

[3] Patel, D., Mehta, K., & Joshi, V. (2019). Biological evaluation of thiadiazole compounds for diabetes management. *International Journal of Diabetes and Metabolism*, 11(2), 101–113.

[4] Sharma, V., Singh, K., & Rana, T. (2018). Synthesis and in vivo evaluation of antidiabetic thiadiazole derivatives. *Pharmaceutical Chemistry Journal*, 23(1), 33–45.

[5] Verma, L., Dixit, A., & Rao, M. (2017). Structure-activity relationship of thiadiazole derivatives with antidiabetic potential. *Bioorganic & Medicinal Chemistry Letters*, 27(7), 1400–1408.

[6] Gupta, R., Singh, P., & Mehra, A. (2016). Pharmacological screening of thiadiazole derivatives in diabetic models. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 31(5), 745–753.

[7] Rao, N., Kumar, D., & Singh, J. (2015). Effect of functionalized thiadiazole derivatives on hyperglycemia and oxidative stress. *Diabetes Research and Clinical Practice*, 109(2), 248–258.

[8] Jain, M., Sharma, P., & Kaur, H. (2014). Alpha-glucosidase inhibition by novel thiadiazole derivatives: Synthesis and evaluation. *Chemical Biology & Drug Design*, 83(1), 37–46.

[9] Khan, F., Ali, S., & Malik, R. (2013). Antioxidant and antidiabetic activity of thiadiazole derivatives in streptozotocin-induced diabetic rats. *European Journal of Pharmacology*, 701(1–3), 22–29.

[10] Ali, M., Riaz, M., & Qureshi, S. (2012). Synthesis and biological evaluation of thiadiazole-based alpha-amylase and alpha-glucosidase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 27(4), 526–534.

[11] Mehta, K., Patel, V., & Desai, R. (2011). Multifunctional antidiabetic agents: Design and evaluation of thiadiazole derivatives. *Bioorganic Chemistry*, 39(3), 78–86.

[12] Singh, D., & Chauhan, A. (2010). Synthesis and antidiabetic activity of halogen-substituted thiadiazole derivatives. *Medicinal Chemistry Research*, 19(8), 873–882.

[13] Verma, S., & Srivastava, P. (2009). Biological screening of thiadiazole derivatives for antidiabetic properties. *European Journal of Medicinal Chemistry*, 44(6), 2431–2437.

[14] Patel, R., & Joshi, M. (2008). Inhibitory effect of novel thiadiazole derivatives on carbohydrate metabolizing enzymes. *Journal of Chemical and Pharmaceutical Research*, 1(1), 22–30.

[15] Reddy, T., Narayana, M., & Krishna, V. (2007). Antidiabetic and antioxidant activities of thiadiazole derivatives in experimental diabetes. *Pharmaceutical Biology*, 45(5), 393–399.